同义名 :	(S)-Pramipexole (hydrochloride); SND919; (–)-Pramipexole
	CAS号 :	104632-25-9
	货号 :	A115399
	分子式 :	C10H19Cl2N3S
	纯度 :	98%
	分子量 :	284.25
	MDL号 :	MFCD00876894
	存储条件：	Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Pramipexole (Dihydrochloride) is a nonergolinic dopamine agonist, with high affinity for the D2 subfamily of dopamine receptors. Pramipexole is efficacious for the symptomatic treatment of early Parkinson's Disease (PD) and its early use, before that of levodopa can delay the emergence of levodopa-related motor complication[3]. Pramipexole is a potent dopamine autoreceptor agonist. Two measurements of receptor activation for dopamine D2, D3, and D4 receptors show that pramipexole is most potent for activation of D3 receptors[4]. Post-stroke treatment with pramipexole reduced levels of mitochondrial ROS and Ca2+ after ischemia. Pramipexole elevated the mitochondrial membrane potential and mitochondrial oxidative phosphorylation. Thus, post-stroke administration of pramipexole induces the neurological recovery through mitochondrial pathways in ischemia/reperfusion injury[5]. P-CNs (Pramipexole dihydrochloride loaded chitosan nanoparticles) enhanced antioxidant status in the form of increased superoxide dismutase and catalase activities, along with increased dopamine level in the brain significantly[6]. Half of the patients stopped the pramipexole an average of 2 months after starting it. For all patients, depressed mood, and the total profile of depressive symptoms improved significantly within 4 weeks and remained significantly improved for as long as 36 weeks[7].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00614575	-		Completed	-	-
NCT00614575	-		Completed	-	-
NCT00144209	Restless Legs Syndrome	Phase 3	Completed	-	Switzerland ... 展开 >> Boehringer Ingelheim Investigational Site Basel, Switzerland, 4025 Boehringer Ingelheim Investigational Site Basel, Switzerland, 4031 Boehringer Ingelheim Investigational Site Bern, Switzerland, 3000 Boehringer Ingelheim Investigational Site Lugano, Switzerland, CH-6900 Boehringer Ingelheim Investigational Site Zurich, Switzerland, 8091 Boehringer Ingelheim Investigational Site Zurzach, Switzerland, 5330 收起 <<

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	3.52mL 0.70mL 0.35mL	17.59mL 3.52mL 1.76mL	35.18mL 7.04mL 3.52mL

参考文献

[1]Pathare DB, Jadhav AS, Shingare MS. Validated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride monohydrate. J Pharm Biomed Anal. 2006 Jun 16;41(4):1152-6. [2]Mierau J, Schneider FJ, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [3]Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother. 2011;11(7):925‐935 [4]Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995;290(1):29‐36 [5]Andrabi SS, Ali M, Tabassum H, Parveen S, Parvez S. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019;12(8):dmm033860. [6]Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;109:27‐35 [7]El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010;81(3):207‐213